CN116075502B - 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法 - Google Patents

用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法 Download PDF

Info

Publication number
CN116075502B
CN116075502B CN202180026783.9A CN202180026783A CN116075502B CN 116075502 B CN116075502 B CN 116075502B CN 202180026783 A CN202180026783 A CN 202180026783A CN 116075502 B CN116075502 B CN 116075502B
Authority
CN
China
Prior art keywords
group
groups
alkyl
ring
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180026783.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116075502A (zh
Inventor
T-S·宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of CN116075502A publication Critical patent/CN116075502A/zh
Application granted granted Critical
Publication of CN116075502B publication Critical patent/CN116075502B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180026783.9A 2020-03-30 2021-03-18 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法 Active CN116075502B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US63/001,723 2020-03-30
US202063053908P 2020-07-20 2020-07-20
US63/053,908 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (2)

Publication Number Publication Date
CN116075502A CN116075502A (zh) 2023-05-05
CN116075502B true CN116075502B (zh) 2024-04-12

Family

ID=77920792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026783.9A Active CN116075502B (zh) 2020-03-30 2021-03-18 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法

Country Status (11)

Country Link
US (2) US20210308137A1 (https=)
EP (2) EP4126846A1 (https=)
JP (2) JP2023520883A (https=)
KR (2) KR20230004550A (https=)
CN (1) CN116075502B (https=)
AU (2) AU2021249224A1 (https=)
BR (2) BR112022019558A2 (https=)
CA (2) CA3179167A1 (https=)
IL (2) IL296927B2 (https=)
TW (2) TW202203914A (https=)
WO (2) WO2021202114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528704A (zh) * 2006-09-01 2009-09-09 赛林药物股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
CN104844605A (zh) * 2014-02-13 2015-08-19 生华生物科技股份有限公司 吡唑并嘧啶前药及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
US20110071136A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
WO2021195126A1 (en) * 2020-03-24 2021-09-30 Burnet Michael W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528704A (zh) * 2006-09-01 2009-09-09 赛林药物股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
CN104844605A (zh) * 2014-02-13 2015-08-19 生华生物科技股份有限公司 吡唑并嘧啶前药及其制备方法和应用

Also Published As

Publication number Publication date
CN116075502A (zh) 2023-05-05
EP4126846A1 (en) 2023-02-08
CA3179167A1 (en) 2021-10-07
AU2021249224A1 (en) 2022-12-01
IL296927B1 (en) 2025-07-01
US20210308110A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
EP4126845A4 (en) 2024-05-01
US20210308137A1 (en) 2021-10-07
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
KR20230004550A (ko) 2023-01-06
JP2023520882A (ja) 2023-05-22
TW202203915A (zh) 2022-02-01
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
US11696911B2 (en) 2023-07-11
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
JP2023520883A (ja) 2023-05-22
BR112022019558A2 (pt) 2022-12-06
IL296927B2 (en) 2025-11-01
IL296927A (en) 2022-12-01
TW202203914A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
RU2718690C2 (ru) Способы и композиции для ингибирования полимеразы
WO2018043747A1 (ja) 抗ｂ型肝炎ウイルス剤
ES2954126T3 (es) Derivados del pirazolo[1,5-a]pirimidina-7-amina útiles en terapia
WO2007139150A1 (ja) ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
CN116075502B (zh) 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
WO2004052879A1 (en) Thiophenederivatives for the treatment of flavivirus infections
CN113286798B (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112118891A (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
CN108349907B (zh) 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN114159445B (zh) 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
JP7717704B2 (ja) Ｂ型肝炎ウイルスのスピロ環式阻害剤
CN110437232A (zh) 双并环脲类核衣壳抑制剂及其药物用途
CN1980657A (zh) 新颖的抗病毒赛菊宁黄质类似物
RU2407738C1 (ru) Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
CN107074876A (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
JP2023526345A (ja) Ｂ型肝炎の治療に使用される組み合わせ
NZ733805B2 (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
BR122021002683B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv
BR112017019758B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv
HK1103626A (en) Novel antiviral helioxanthin analogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40086507

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant